ACTOplus met Approval History

• FDA approved: Yes (First approved August 29th, 2005)
• Brand name: ACTOplus met
• Generic name: pioglitazone and metformin
• Company: Takeda Pharmaceuticals
• Treatment for: Diabetes, Type 2

ACTOplus met (pioglitazone and metformin) is a combination antihyperglycemic medication used in the management of type 2 diabetes.

FDA Approval History for ACTOplus met

Date	Article
May 13, 2009	FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Aug 29, 2005	ACTOplus met Takeda Pharmaceuticals - Treatment for Type 2 Diabetes
Oct 29, 2004	Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus Met (pioglitazone HCl and metformin HCl)

See also...

ACTOplus met (pioglitazone and metformin) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.